US Edition
AbelZeta Presents New Data on C-CAR168 for the Treatment of Autoimmune Diseases at LUPUS 2025
- On May 22, 2025, AbelZeta Pharma presented Phase 1 data from its first-in-human trial of C-CAR168 at LUPUS 2025 in Toronto, Canada.
- The clearance of C-CAR168's Investigational New Drug application by the FDA and its design as a bi-specific CAR-T therapy targeting CD20 and BCMA enabled this study in refractory autoimmune diseases.
- The open-label, multicenter investigator-initiated trial treated 10 patients with refractory lupus nephritis, systemic lupus erythematosus, and neurological diseases including secondary progressive multiple sclerosis.
- As of February 28, 2025, the therapy was well tolerated with mainly low-grade cytokine release syndrome and robust B cell depletion, while four lupus nephritis patients achieved SRI and the SPMS patient showed significant neurological improvements.
- These results suggest a meaningful advancement in treating severe autoimmune diseases and support further C-CAR168 development with planned Phase 1b and Phase 2 studies.
Insights by Ground AI
Does this summary seem wrong?
37 Articles
37 Articles
All
Left
4
Center
11
Right
2
The Conway Daily Sun+36 Reposted by 36 other sources
AbelZeta Presents New Data on C-CAR168 for the Treatment of Autoimmune Diseases at LUPUS 2025
Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy Targeting Lupus Nephritis, Systemic Lupus Erythematosus and Multiple Sclerosis Phase 1, First-in-Human Investigator-Initiated Trial (IIT)
Coverage Details
Total News Sources37
Leaning Left4Leaning Right2Center11Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
L 24%
C 65%
12%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
